Compare TDOC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | NNNN |
|---|---|---|
| Founded | 2002 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | N/A |
| Metric | TDOC | NNNN |
|---|---|---|
| Price | $7.34 | $15.59 |
| Analyst Decision | Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $7.56 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 19.5K |
| Earning Date | 04-29-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $10.50 |
| 52 Week High | $9.77 | $55.65 |
| Indicator | TDOC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 28.31 |
| Support Level | $6.88 | $10.50 |
| Resistance Level | $7.39 | $31.12 |
| Average True Range (ATR) | 0.42 | 3.72 |
| MACD | -0.03 | -1.87 |
| Stochastic Oscillator | 50.93 | 4.52 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).